<DOC>
	<DOC>NCT01229267</DOC>
	<brief_summary>This is a study to determine whether investigational V212 reduces the incidence of herpes zoster (HZ) compared to placebo when administered to recipients of autologous hematopoietic cell transplants (HCT).</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (Study No. V212-001 AM4)</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Men and women at least 18 years of age Has prior history of varicella, antibodies to VZV (documented prior to receipt of blood products), or residence in a country with endemic VZV infection for â‰¥30 years or if participant is &lt;30 years old, attended primary or secondary school in a country with endemic VZV infection. Scheduled to undergo an autologous hematopoietic cell transplant within 60 days of enrollment Is highly unlikely to conceive during the time period starting 2 weeks prior to enrollment through 6 months from last vaccination dose Female participants of childbearing potential must have a negative serum or urine pregnancy test. History of hypersensitivity reaction to any vaccine component Prior history of herpes zoster within 1 year of enrollment Prior receipt of any varicella or zoster vaccine More than 2 relapses of the underlying cancer (participants with Hodgkin's lymphoma may have had more than 2 relapses) Expectation of tandem transplant procedure Is expected to receive &gt;6 months (&gt;180 days) of prophylactic antiviral therapy postHCT. Is pregnant or breastfeeding or expecting to conceive within the period of 2 weeks prior to enrollment through 6 months from last vaccination dose. Has received a live virus vaccine or is scheduled to receive a live virus vaccine in the period from 4 weeks prior to Dose 1 through 28 days Postdose 4. Has received an inactivated vaccine or is scheduled to receive an inactivated vaccine in the period between 7 days prior to and 28 days following Doses 1 through 4.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Herpes zoster</keyword>
	<keyword>vaccine</keyword>
	<keyword>herpes zoster-related complications</keyword>
	<keyword>immunocompromised</keyword>
	<keyword>autologous hematopoietic cell transplants</keyword>
</DOC>